Khetsuriani Nino, Perehinets Ihor, Nitzan Dorit, Popovic Dragoslav, Moran Thomas, Allahverdiyeva Vusala, Huseynov Shahin, Gavrilin Eugene, Slobodianyk Liudmyla, Izhyk Olha, Sukhodolska Anna, Hegazi Sahar, Bulavinova Katerina, Platov Sergei, O'Connor Patrick
World Health Organization Regional Office for Europe, Copenhagen, Denmark; Centers for Disease Control and Prevention, Atlanta, GA, USA.
Ministry of Health of Ukraine, Kyiv, Ukraine.
Vaccine. 2017 Aug 24;35(36):4769-4776. doi: 10.1016/j.vaccine.2017.04.036. Epub 2017 May 19.
The European Region, certified polio-free in 2002, remains at risk of wild poliovirus reintroduction and emergence of circulating vaccine-derived polioviruses (cVDPV) until global polio eradication is achieved, as demonstrated by the cVDPV1 outbreak in Ukraine in 2015.
We reviewed epidemiologic, clinical and virology data on cVDPV cases, surveillance and immunization coverage data, and reports of outbreak-related surveys, country missions, and expert group meetings.
In Ukraine, 3-dose polio vaccine coverage declined from 91% in 2008 to 15% by mid-2015. In summer, 2015, two unrelated children from Zakarpattya province were paralyzed by a highly divergent cVDPV1. The isolates were 20 and 26 nucleotide divergent from prototype Sabin strain (with 18 identical mutations) consistent with their common origin and ∼2-year evolution. Outbreak response recommendations developed with international partner support included conducting three nationwide supplementary immunization activities (SIAs) with tOPV, strengthening surveillance and implementing communication interventions. SIAs were conducted during October 2015-February 2016 (officially reported coverage, round 1-64.4%, round 2-71.7%, and round 3-80.7%). Substantial challenges to outbreak response included lack of high-level support, resistance to OPV use, low perceived risk of polio, widespread vaccine hesitancy, anti-vaccine media environment, economic crisis and military conflict. Communication activities improved caregiver awareness of polio and confidence in vaccination. Surveillance was enhanced but did not consistently meet applicable performance standards. Post-outbreak assessments concluded that cVDPV1 transmission in Ukraine has likely stopped following the response, but significant gaps in population immunity and surveillance remained.
Chronic under-vaccination in Ukraine resulted in the accumulation of children susceptible to polioviruses and created favorable conditions for VDPV1 emergence and circulation, leading to the outbreak. Until programmatic gaps in immunization and surveillance are addressed, Ukraine will remain at high-risk for VDPV emergence and circulation, as well as at risk for other vaccine-preventable diseases.
欧洲区域于2002年被认证为无脊髓灰质炎,但在全球消灭脊髓灰质炎之前,仍面临野生脊髓灰质炎病毒重新引入和循环疫苗衍生脊髓灰质炎病毒(cVDPV)出现的风险,2015年乌克兰的cVDPV1疫情就证明了这一点。
我们审查了cVDPV病例的流行病学、临床和病毒学数据、监测和免疫接种覆盖率数据,以及疫情相关调查、国家访问和专家组会议的报告。
在乌克兰,三剂脊髓灰质炎疫苗接种覆盖率从2008年的91%下降到2015年年中时的15%。2015年夏季,外喀尔巴阡州两名不相关的儿童因高度变异的cVDPV1而瘫痪。分离株与原型萨宾株有20和26个核苷酸差异(有18个相同突变),这与其共同起源和大约两年的进化一致。在国际伙伴支持下制定的疫情应对建议包括开展三轮全国性口服脊髓灰质炎疫苗补充免疫活动(SIAs)、加强监测和实施宣传干预措施。SIAs在2015年10月至2016年2月期间开展(官方报告的覆盖率,第一轮为64.4%,第二轮为71.7%,第三轮为80.7%)。疫情应对面临的重大挑战包括缺乏高层支持、对口服脊髓灰质炎疫苗使用的抵制、对脊髓灰质炎的低感知风险、广泛的疫苗犹豫、反疫苗媒体环境、经济危机和军事冲突。宣传活动提高了护理人员对脊髓灰质炎的认识和对疫苗接种的信心。监测得到了加强,但并未始终达到适用的绩效标准。疫情后评估得出结论,在采取应对措施后,乌克兰的cVDPV1传播可能已经停止,但人群免疫和监测方面仍存在重大差距。
乌克兰长期疫苗接种不足导致易感染脊髓灰质炎病毒的儿童数量积累,并为VDPV1的出现和传播创造了有利条件,从而引发了疫情。在免疫和监测方面的规划差距得到解决之前,乌克兰仍将面临VDPV出现和传播的高风险,以及其他疫苗可预防疾病的风险。